Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Gregoire Calon"'
Autor:
Gregoire Calon, Virginia O. Volpe, Chetasi Talati, Abida Babu, Constantine Logothetis, Andrew T. Kuykendall, Nicole D. Vincelette, Pukhraz Basra, Jeffrey E. Lancet, David Gajzer, Rami S. Komrokji, Seongseok Yun, Qianxing Mo, David A. Sallman, Najla Al Ali, Kendra Sweet, Eric Padron, Onyee Chan, Ling Zhang
Publikováno v:
Leuk Res
Recent studies demonstrated that MYC epigenetically regulates AML cell survival and differentiation by suppressing IDH1/2-TET2-5hmC signaling and that MYC overexpression is associated with poor survival outcomes in multiple AML patient cohorts. Howev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0684f69917ef85168767121d2f908f0
https://pubmed.ncbi.nlm.nih.gov/34749168
https://pubmed.ncbi.nlm.nih.gov/34749168
Autor:
Virginia Olivia Volpe, Nicole D. Vincelette, Onyee Chan, Chetasi Talati, Kendra Sweet, Andrew T. Kuykendall, Constantine Logothetis, Rami S. Komrokji, Gregoire Calon, Nathan P. Horvat, David A. Sallman, Eric Padron, Ling Zhang, Seongseok Yun
Publikováno v:
Blood. 138:2377-2377
Background In AML, IDH1/2 somatic mutations can be frequent in patients at about 20%. Physiologically, IDH1/2 catalyze isocitrate conversion to alpha-ketoglutarate (α-KG). α-KG is an activating co-factor for ten-eleven translocation 2 (TET2), an im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::caf9618d241eebfd5db2cdc56b6d8929
https://doi.org/10.1182/blood-2021-147030
https://doi.org/10.1182/blood-2021-147030
Autor:
Ling Zhang, Kendra Sweet, Nathan P. Horvat, Virginia O. Volpe, Eric Padron, Nicole D. Vincelette, Chetasi Talati, Seongseok Yun, Gregoire Calon, Onyee Chan, Constantine Logothetis, David A. Sallman, Jeffrey E. Lancet, Rami S. Komrokji, Andrew T. Kuykendall
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S212
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97ef3ee80cbd835c41e0b896dc21913f
https://doi.org/10.1016/s2152-2650(21)01331-8
https://doi.org/10.1016/s2152-2650(21)01331-8
Autor:
Andrew T. Kuykendall, Virginia O. Volpe, Rami S. Komrokji, Ling Zhang, Constantine Logothetis, Eric Padron, Jeffrey E. Lancet, Nathan P. Horvat, Gregoire Calon, Seongseok Yun, Nicole D. Vincelette, Onyee Chan, Kendra Sweet, David A. Sallman, Chetasi Talati
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S286
Context: Clinical trials of IDH1/2 inhibitors demonstrated promising outcomes in IDH1/2mut AML patients. However, a substantial fraction of patients fail to respond to IDH1/2 inhibitors in AML. Recent preclinical studies have shown MYC prevents the n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b0d9e6a952af720fac3441c2d273d05
https://doi.org/10.1016/s2152-2650(21)01686-4
https://doi.org/10.1016/s2152-2650(21)01686-4
Autor:
Kendra Sweet, Gregoire Calon, David A. Sallman, Rami S. Komrokji, Onyee Chan, Ling Zhang, Virginia O. Volpe, Andrew T. Kuykendall, Constantine Logothetis, Eric Padron, Nathan P. Horvat, Seongseok Yun, Chetasi Talati, Nicole D. Vincelette, Jeffrey E. Lancet
Publikováno v:
Journal of Clinical Oncology. 39:e19010-e19010
e19010 Background: Recent studies showed that IDH1/2 are frequently mutated in AML and that aberrant 2-HG elevation driven by the mutant IDH1/2 proteins plays a pivotal role in AML development. Subsequent clinical trials of IDH1/2 inhibitors demonstr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::04dcdd2021a521f4a285f3db50b46d16
https://doi.org/10.1200/jco.2021.39.15_suppl.e19010
https://doi.org/10.1200/jco.2021.39.15_suppl.e19010